Get the Stockscreener App
26.18
0.15%
0.04
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $26.18, with a volume of 48.41M.
It is up +0.15% in the last 24 hours and down -0.30% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$26.14
Open:
$26.19
24h Volume:
48.41M
Relative Volume:
1.31
Market Cap:
$149.21B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
20.07
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
+1.08%
1M Performance:
-0.30%
6M Performance:
+1.71%
1Y Performance:
+11.64%
1-Day Range:
$25.93
$26.24
1-Week Range:
$25.66
$26.54
52-Week Range:
$23.06
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.18 | 148.98B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,105.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.33 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
217.72 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
118.72 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.67 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Comirnaty and Pfizer's mRNA vaccine in the U.S. market - AD HOC NEWS
Is Pfizer Stock a "Value Trap" or a Generational Opportunity? - Yahoo Finance
Pfizer (PFE) Reports Promising Results from Breakwater Trial - GuruFocus
Pfizer (PFE) Unveils Promising Talzenna Study Results for Prosta - GuruFocus
Pfizer Inc. stock (US7170811035): TALZENNA plus XTANDI data and stakeholder moves keep focus on onco - AD HOC NEWS
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer - Business Wire
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
Pfizer Strikes Up To $10.5 Billion Deal With China's Innovent Biologics To Develop Next-Gen Cancer Therapies - Yahoo Finance
Why Wall Street Is Dead Wrong About This Popular Stock - The Motley Fool
Pfizer says Talzenna plus Xtandi improves radiographic progression-free survival by over 50% in metastatic prostate cancer - marketscreener.com
Pfizer’s US$10.5b Oncology Deal With Innovent And What It Means For Valuation - simplywall.st
Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing - MedCity News
Pfizer, HP among top 10 large-cap value stocks - MSN
Pfizer Inks Up to $10.5B Innovent Biotech Licensing Deal - Gotrade
Pfizer School of Science Mobile Experience Makes STEM Learning Fun - PIX11
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal - BioWorld News
Pfizer’s VESPER-4 Obesity Trial Signals a Serious Push Into the GLP-1 Growth Market - TipRanks
Pfizer says EC authorizes update to pediatric use of Pfizer & BioNTech Covid 19 vaccine - marketscreener.com
Pfizer Inc. stock (US7170811035): Oncology deal with Innovent reshapes pipeline focus - AD HOC NEWS
Pfizer (PFE) Reveals Promising Seven-Year Findings from CROWN Tr - GuruFocus
Pfizer (PFE) Among Most Attractively Valued U.S. Stocks - GuruFocus
Pfizer, Innovent strike $10B cancer drug deal - BioPharma Dive
Pfizer Expands Oncology Pipeline in $10.5B Innovent Deal - GuruFocus
Turning Silence Into Advocacy: Women Reshaping Cancer Conversations - Pfizer
Pfizer's Lorbrena Shows 55% Likelihood of Progression-Free Survival After Seven Years in NSCLC Study - marketscreener.com
Pfizer, Innovent Strike $10.5 Billion Oncology Deal to Develop 12 Cancer Medicines - Contract Pharma
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer - Business Wire
Pfizer and Innovent Biologics sign $10.5B cancer drug deal - Yahoo Finance
Pfizer partners with Innovent for $10.5bn to advance ADC oncology medicines - European Pharmaceutical Review
Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal - Pharmaceutical Technology
Pfizer and China's Innovent sign major deal on cancer treatment - medwatch.com
Pfizer (PFE) Partners with Innovent Biologics in $10.5B Oncology Deal - GuruFocus
PFE Stock Quote Price and Forecast - CNN
Pfizer, Innovent Biologics Strike Cancer Drug Partnership Worth up to $10.5 Billion - marketscreener.com
Pfizer signs up to $10.5B oncology deal with China’s Innovent (PFE:NYSE) - Seeking Alpha
Innovent Biologics and Pfizer Joint Development of 12 Oncology ProgrammesNews and Statistics - IndexBox
Innovent Biologics, Pfizer strike $10.5 billion cancer drug deal amid China biotech boom - WKZO
Pfizer inks up to $10.5 billion deal with China’s Innovent Biologics - BusinessLine
Innovent Biologics, Pfizer strike US$10.5 bil cancer drug deal amid China biotech boom - The Edge Malaysia
Pfizer Inks Up to $10.5 Billion Deal With China’s Innovent - Bloomberg.com
INNOVENT BIO Leaps ~8% on Strategic Collaboration with Pfizer Covering 12 Projects - AASTOCKS.com
INNOVENT BIO Forms Strategic Collaboration with Pfizer on 12 Projects with Total Deal Value of USD10.5B - AASTOCKS.com
Pfizer inks up to $10.5 billion deal With China’s Innovent - Moneycontrol.com
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines - The Manila Times
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal - Reuters
Should Pfizer’s (PFE) New 25‑Valent Vaccine Data and Oncology Alliance Require Action From Investors? - simplywall.st
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines - Business Wire
Pfizer, Innovent Sign Licensing Deal to Develop 12 Cancer Drugs - marketscreener.com
Wardlaw+Hartridge Student Receives Pfizer Scholarship - TAPinto
Pfizer’s New Phase 1 Trial Signals Steady Early-Stage Pipeline Progress - TipRanks
For this Pfizer Scientist, Cancer Research is Personal - Pfizer
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.31%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):